Select Medical Holdings CORP

Select Medical Holdings Corporation announced the completion of its acquisition by a consortium led by its Executive Chairman, Robert A. Ortenzio, and Welsh, Carson, Anderson & Stowe (WCAS), valuing the company at approximately $3.9 billion.

Select Medical stockholders have voted to approve the company's acquisition by a consortium led by its own executives and WCAS.

Select Medical reported Q1 2026 revenue growth of 5.0% to $1.42 billion while progressing toward a $16.50 per share take-private merger.

Select Medical Holdings Corporation stockholders approved all management proposals at the 2026 Annual Meeting, including a board declassification amendment.

Select Medical Holdings Corporation announced a definitive agreement to be acquired by a consortium led by its executive chairman, co-founder, and WCAS for $16.50 per share in cash, valuing the company at $3.9 billion.

Select Medical Holdings Corporation announced robust financial results for its fourth quarter and full year ended December 31, 2025, alongside a cash dividend declaration and a 2026 business outlook.

Select Medical reports Q1 2026 financial results while progressing toward a $16.50 per share cash acquisition by a consortium led by company leadership.

Select Medical Holdings Corporation reported increased revenue and income from continuing operations for Q3 2025, driven by rehabilitation segments, but faces challenges from new healthcare regulations and ongoing litigation.

Select Medical Holdings Corporation reported increased revenue and income from continuing operations for the second quarter and first half of 2025, driven by strong performance in its Rehabilitation and Outpatient segments, despite a decline in its Critical Illness Recovery Hospital segment and ongoing legal and regulatory uncertainties.

Select Medical Holdings saw a revenue increase in Q1 2025, but net income decreased due to the spin-off of Concentra.

Select Medical Holdings Corporation saw revenue and earnings growth in the third quarter of 2024, while also completing the initial public offering of its Concentra subsidiary.

Select Medical Holdings Corporation reported a slight decrease in income from operations despite a revenue increase in its second quarter, while also completing the initial public offering of its Concentra subsidiary.

Select Medical Holdings Corporation reported a significant increase in income from continuing operations for 2025, alongside strategic executive promotions and ongoing evaluation of a take-private proposal.

Select Medical Holdings Corporation announces its 2024 financial results, including a revenue of $5.2 billion and the completion of the spin-off of Concentra.

Select Medical Holdings Corporation files its 10-K report for the year ended December 31, 2023, detailing financial performance and announcing the planned separation of its Concentra business.

Select Medical Holdings Corp. reports a director's completion of a merger transaction, converting common stock into cash consideration.

Katherine R. Davisson, a Director at Select Medical Holdings Corp., reported a transaction related to the company's merger, converting shares into cash consideration.

William H. Frist reported a disposition of Select Medical Holdings Corp. common stock following a merger agreement, converting shares into cash consideration.

Marilyn B. Tavenner, a Director at Select Medical Holdings Corp., has reported the conversion of her common stock into cash following the company's merger.

Select Medical Holdings Corp. Director Thomas Daniel reports on the conversion of his common stock into cash consideration following a merger agreement.

Parvinderjit S. Khanuja reports a transaction related to the merger of Select Medical Holdings Corp, converting shares to cash consideration.

Select Medical Holdings Corporation announces its 2026 Annual Meeting of Stockholders to address director elections, executive compensation, auditor ratification, board declassification, and special meeting rights.

Select Medical Holdings Corporation amends its definitive proxy statement to clarify the effect of broker non-votes on Proposal 3.

Select Medical Holdings Corporation will hold its annual stockholder meeting virtually on April 24, 2025, to vote on key proposals including director elections and executive compensation.

Select Medical Holdings Corporation will hold its 2025 Annual Meeting of Stockholders virtually on April 24, 2025, to vote on director elections, an amendment to eliminate supermajority voting, director compensation policy, and other proposals.

Select Medical Holdings Corporation amends its definitive proxy statement to correct the number of outstanding shares eligible to vote and clarify the effect of broker non-votes on certain proposals.

Select Medical Holdings Corporation will hold its annual stockholder meeting virtually on April 25, 2024, to vote on director elections, executive compensation, equity incentive plan amendments, auditor ratification, officer exculpation, and a stockholder proposal.

Select Medical Holdings Corporation announced the completion of its acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS) for $16.50 per share.

Select Medical Holdings Corporation has agreed to be acquired by Stallion Intermediate Corporation for $16.50 per share in cash, with key management and an equity investor rolling over significant equity.

Select Medical Holdings Corp's Executive Chairman, Robert A. Ortenzio, has submitted a refined non-binding proposal to acquire all outstanding shares not already owned by the reporting persons for $16.00 per share in cash.

Robert A. Ortenzio and Martin F. Jackson, along with the Estate of Rocco A. Ortenzio, propose to acquire all outstanding shares of Select Medical Holdings Corp not already owned by them for $16.00 to $16.20 per share in cash.

Vanguard Portfolio Management has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Select Medical Holdings Corp. common stock as of June 30, 2026.

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 5.21% in Select Medical Holdings Corporation's common stock.

Vanguard Portfolio Management has reported a beneficial ownership of 5.45% in Select Medical Holdings Corp. common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting beneficial ownership of 0.1% of Select Medical Holdings Corp. common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Select Medical Holdings Corp following an internal realignment.

BlackRock, Inc. has filed an Amendment No. 11 to Schedule 13G, disclosing its beneficial ownership of 12.4% of Select Medical Holdings Corp.'s common stock as of March 31, 2025.